SEC Form 4 · accession 0001104659-18-058474
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy B Lowinger
Officer — Chief Scientific Officer
Period of report
Sep 24, 2018
Accepted (ET)
Sep 25, 2018 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 24, 2018 | M | 3,500 | $1.40 | A | 15,991 | D | |
| Common StockF2 | Sep 24, 2018 | S | 3,500 | $11.63 | D | 12,491 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Common StockF3 | $1.40 | Sep 24, 2018 | M | 3,500 | D | — | Oct 1, 2022 | Common Stock | 3,500 | 89,833 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Lowinger's company approved trading plan under Rule 10b5-1.
- F2This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.32 to $11.80, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any other security holder of Mersana Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The option vested 25% on August 1, 2013 and in equal quarterly installments thereafter.